|
Aug 6
|
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
|
|
Jul 27
|
Galapagos Second Quarter 2025 Earnings: Misses Expectations
|
|
Jul 23
|
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
|
|
Jul 23
|
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
|
|
Jul 23
|
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
|
|
May 27
|
Galapagos Creates New Subscription Right Plan
|
|
Apr 26
|
Galapagos First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Apr 23
|
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
|
|
Apr 15
|
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
|
|
Apr 11
|
Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
|
|
Feb 24
|
Galapagos to Present at Upcoming Investor Conferences
|
|
Feb 18
|
Galapagos (AMS:GLPG) adds €185m to market cap in the past 7 days, though investors from five years ago are still down 89%
|
|
Feb 17
|
Galapagos receives transparency notification and 13D filing from Tang Capital
|
|
Feb 5
|
Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Sep 30
|
Galapagos receives transparency notification from EcoR1 Capital
|
|
Jun 14
|
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
|
|
Jun 14
|
Retail investors are Galapagos NV's (AMS:GLPG) biggest owners and were hit after market cap dropped €74m
|
|
May 15
|
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
|
|
May 6
|
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript
|
|
May 4
|
Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
|